Lenalidomide plus R-GDP (R2-GDP) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Final Results of the R2-GDP-GOTEL Trial and Immune Biomarker Subanalysis - Concepedia

Concepedia

Publication | Open Access

Lenalidomide plus R-GDP (R2-GDP) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Final Results of the R2-GDP-GOTEL Trial and Immune Biomarker Subanalysis

DOI Full Paper Access

15

Citations

33

References

2022

Year

Natalia Palazón‐Carrión, Alejandro Martı́n, Esteban Nogales‐Fernández, Carlos Jiménez‐Cortegana, Fernando Carnicero-González, Eduardo Ríos, Fátima de la Cruz‐Vicente, Guillermo Rodríguez‐García, Rubén Fernández-Álvarez, Natividad Martínez-Banaclocha,

Clinical Cancer Research

Abstract

R2-GDP schedule is feasible and highly active in R/R DLBCL, including the primary refractory population. Immune biomarkers showed differences in responders versus progressors.

References

	Year	Citations

Page 1